Moxifloxacin-induced torsades de pointes by Sherazi, Saadia et al.
71www.cardiologyjournal.org
CASE REPORT
Cardiology Journal
2008, Vol. 15, No. 1, pp. 71–73
Copyright © 2008 Via Medica
ISSN 1897–5593
Address for correspondence: Abrar H. Shah, MD
Unity Health System
1561 Long Pond Rd., Suite 401
Rochester, NY 14626, USA
e-mal: Abrar_Shah@urmc.rochester.edu
Received: 29.04.2007 Accepted: 2.01.2008
Moxifloxacin-induced torsade de pointes
Saadia Sherazi1, Michael DiSalle1, James P. Daubert2 and Abrar H. Shah1
1Unity Health System, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA
2Cardiology Division, Department of Medicine, University of Rochester, Medical Center, NY, USA
Abstract
Torsade de pointes (TdP) is increasingly recognized as a complication of drug therapy. The
most common cause of drug-induced QT prolongation is inhibition of the rapidly activating
component of the delayed potassium current (IKr). Moxifloxacin, a widely used fluoroquinolone,
is a weak IKr inhibitor and has been associated with QT prolongation. We report a case of marked
QT prolongation (618 ms) and TdP associated with moxifloxacin use. Although it is difficult to
predict which patients are at risk from TdP, careful assessment of the risk/benefit ratio is impor-
tant before prescribing drugs known to cause QT prolongation. (Cardiol J 2008; 15: 71–73)
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Introduction
Torsade de pointes (TdP), a potentially life-
threatening polymorphic ventricular tachyarrhyth-
mia associated with QT prolongation, is increasingly
recognized as a complication of drug therapy. The
most common cause of drug-induced QT prolonga-
tion is inhibition of the rapidly activating component
of the delayed potassium current (IKr). Moxifloxacin,
a widely used fluoroquinolone, is a weak IKr inhibitor
and has been associated with QT prolongation [1].
Moxifloxacin has not been commonly associated
with drug-induced TdP. We report a case of TdP
associated with moxifloxacin use.
Case report
A 74-year-old man presented with coughing
and chest pain for three days. Past medical history
included coronary artery bypass surgery, conges-
tive heart failure and hypertension. Medications
were pantoprazole, lisinopril, levothyroxine,
celecoxib, furosemide and atorvastatin. Physical
examination was unremarkable except for faint
bibasilar crackles. Laboratory data showed K of
4.3 mmol/L and Mg of 1.2 meq/L. First troponin was
0.54 ng/mL (0–0.79 ng/mL), and the second tropon-
in was 0.18 ng/mL. EKG was unremarkable with
QTc interval of 461 ms. The patient was started on
intravenous moxifloxacin 400 mg as therapy for
presumed community-acquired pneumonia. On the
second day of admission the patient had an episode
of TdP, which progressed to ventricular fibrillation
(VF) and was successfully defibrillated (Fig. 1). An
ECG done immediately after the arrest showed
a QTc of 618 ms (Fig. 2). The patient had one more
episode of VF ten minutes later, which was again
successfully defibrillated. Moxifloxacin was prompt-
ly discontinued and he underwent a cardiac angi-
ogram, which showed patent grafts and no interven-
tion was needed. His QTc upon discharge shortened
to 492 ms, close to his baseline value, but still
abnormally prolonged. In follow-up for one year fol-
lowing the two TdP/VF arrests, he has had no further
recurrence of ventricular tachycardia or syncope.
Discussion
Prolongation of the QT interval has gained in-
creased clinical attention due to its association with
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degeneration into a potentially fatal ventricular ar-
rhythmia known as torsade de pointes. Clinicians
need to be alert to QT prolongation when using cer-
tain pharmacologic agents, especially in patients with
certain identified risk factors for QT prolongation.
Understanding normal cell cardiac cell electro-
physiology is required in order to appreciate fully
the proposed alteration in ion currents and electro-
physiological mechanisms that underlie congenital
or acquired long QT syndrome (LQTS). The normal
depolarization of cardiac cells involves a rapid in-
flow of sodium ions. Repolarization follows when the
outflow of potassium ions exceeds the declining
influx of sodium and calcium ions. In the family of
long QT syndromes, there is a delay in repolariza-
tion due to malfunction of ion channels. The most
common mechanism for LQTS due to drug therapy
is through inhibition of the rapid component of the
delayed rectifier, potassium current (IKr), that is
chiefly responsible for phase 3 repolarization [2].
The proposed mechanism for drug-induced TdP is
the development of early afterdepolarizations
(EAD) when the balance of repolarization and de-
polarization becomes perturbed in phase 3 of the
action potential. An EAD may lead to a triggered
response or action potential. Moxifloxacin is a weak
IKr inhibitor and has been shown to prolong ventricu-
lar repolarization time in healthy individuals at
standard (400 mg) and supratherapeutic (800 mg)
doses [1]. In the range of doses tested, this length-
ening was not dose dependent but was correlated
to plasma moxifloxacin concentration. Moxifloxacin
is implicated in this patient’s TdP as it was the only
new medication administered to him that has previ-
ously been associated with QT interval prolongation.
Although he had pre-existing risk factors for TdP,
including prolonged QTc, further QTc interval pro-
longation and TdP did not occur until moxifloxacin
Figure 1. The polymorphic ventricular tachycardia in the acquired form is most commonly precipitated by short-
-long-short RR intervals (as shown here). This interval is normally caused by a ventricular premature beat followed
by a compensatory pause. This can also occur in association with bradycardia or frequent pauses; as a result, the
acquired form of long QT syndrome is known as ‘pause-dependent’ [9].
Figure 2. 12-Lead ECG after torsade de pointes showing QTc interval of 618 ms.
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was initiated, and the QTc improved after moxi-
floxacin discontinuation. The patient did not have
any recurrent arrhythmia over one year of follow
up. The proarrhythmic risks of fluoroquinolones are
receiving attention because of the increasingly
widespread use of this class of antibiotics [3]. Cip-
rofloxacin, levofloxacin and gatifloxacin have been
reported to be associated with TdP [4]. Grepa-
floxacin was withdrawn from the market because
of QTc prolongation and risk of TdP. The reason
that some patients develop this side effect while
receiving a drug from this class whereas most pa-
tients do not is probably due at least in part to sub-
clinical mutations and polymorphisms. Recent data
have confirmed that some cases of drug-induced
LQTS and TdP may have ‘silent’ genetic defects in
cardiac ion channel genes [5]. This may create a vul-
nerable substrate that, in the presence of appropri-
ate triggers such as IKr blockers, may precipitate
LQTS and TdP in non-penetrant or weakly pene-
trant gene mutation carriers. Our patient had mild-
ly prolonged QTc even before the initiation of QT
prolonging medication, which could be due to a ‘si-
lent’ genetic defect in the ion channel. In all pub-
lished cases of TdP associated with fluoroquinolo-
nes, patients had one or more concomitant risk fac-
tors including QTc interval > 500 ms, QTc
prolongation > 60 ms from pretreatment value,
hypokalemia, hypomagnesemia, female gender, left
ventricular dysfunction, advanced age, bradycardia
and a possible genetic predisposition for this ar-
rhythmia [6, 7].
Management of patients with acquired LQTS
and TdP requires immediate measures to suppress
the tachyarrhythmia. Intravenous magnesium sul-
phate has been shown to suppress the TdP without
directly shortening the prolonged QT interval [8].
Increasing the heart rate by administration of either
atropine or isoproterenol or, preferably in a control-
led fashion, by temporary ventricular pacing is of-
ten successful in suppressing the arrhythmia. An
increased heart rate results in shortening of the
action potential duration and QT interval and sup-
pression of EADs. Long-term measures include
correction of underlying electrolyte abnormalities
and, particularly, discontinuation of the offending
agent.
Conclusions
Although it is difficult to predict which patients
are at risk from TdP, careful assessment of the risk/
benefit ratio is important before prescribing drugs
known to cause QT prolongation.
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